Well Referenced

Tag: immune checkpoint inhibitors

Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials

This network meta-analysis synthesized data from nine phase III randomized controlled trials to assess the relative efficacy of various first-line systemic therapies for unresectable hepatocellular carcinoma (HCC). The study found that combinations of immune checkpoint inhibitors (ICIs) and anti-VEGF agents, particularly atezolizumab plus bevacizumab, demonstrated the most favorable outcomes in

Read More »
June 26, 2025 No Comments

Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer

This observational cohort study evaluated the clinical safety of combining immune checkpoint inhibitors (ICIs) with Viscum album L. (mistletoe) extract in patients with advanced or metastatic cancer. Sixteen patients were included, with nine receiving both ICI and mistletoe therapy. The study found no statistically significant increase in adverse events (67%

Read More »
June 26, 2025 No Comments